ArticleFrontiers in immunology2026
Multi-omics integration reveals vaccine-specific molecular signatures and temporal dynamics of COVID-19 immune responses.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Vaccination elicits systemic immune responses that extend beyond antibody and lymphocyte activation, engaging coordinated metabolic and lipid pathways that modulate immune function. Nevertheless, how systemic molecular responses differ across COVID-19 vaccine platforms, including closely related mRNA platforms, remains poorly understood. Here, we performed integrated plasma proteomic, lipidomic, and metabolomic profiling of 53 SARS-CoV-2-naïve adults vaccinated with Pfizer-BioNTech, Moderna, or AstraZeneca COVID-19 vaccines. Samples were analysed across multiple timepoints using differential analysis and DIABLO-based multi-omics integration. Our findings reveal distinct platform-associated multi-omic molecular signatures not captured by unsupervised analyses alone. Pfizer-BioNTech vaccination was associated with widespread increases in immunoglobulin and complement associated proteins, together with broad decreases in lipid abundance and bidirectional metabolite changes. In contrast, the Moderna vaccination was associated with predominantly increased lipid abundance and bidirectional metabolite changes, with minimal univariate proteomic changes. AstraZeneca induced subtler yet coherent cross-omic shifts, detectable only through integrative modelling approaches. Despite these platform-associated differences, Pfizer and Moderna shared concordant changes in a subset of metabolites, including amino-acid and TCA-cycle-associated features, within divergent lipidomic contexts. These findings demonstrate that even closely related mRNA vaccine platforms are associated with distinct systemic molecular response patterns. This study establishes integration of multi-omics (as opposed to separate single-omic analyses) as a powerful framework for characterising vaccine-associated molecular responses, identifying candidate platform-specific molecular markers, and providing candidates for future molecular stratification studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.